Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema
Anthony S Basile,1 Matthew M Hutmacher,2 Kenneth G Kowalski,2 Kuan Y Gandelman,3 Dana J Nickens1 1Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc, San Diego, CA, USA; 2Ann Arbor Pharmacometrics Group, Ann Arbor, MI, USA; 3Clinical Pharmacology, World Wide Biopharmaceuticals, Pfizer...
Guardado en:
Autores principales: | Basile AS, Hutmacher MM, Kowalski KG, Gandelman KY, Nickens DJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c12c2369c69545bb9abac183533439d1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
por: Udaondo P, et al.
Publicado: (2011) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sobha Sivaprasad
Publicado: (2008) -
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
por: Sivaprasad S, et al.
Publicado: (2014) -
Clinical experience with pegaptanib sodium
por: Chiara Rosina, et al.
Publicado: (2008) -
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sobha Sivaprasad, et al.
Publicado: (2008)